Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Blauvelt, A, K Reich, K A Papp, A B Kimball, M Gooderham, S K Tyring, R Sinclair, et al. 2018. “Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomized Controlled Trials.”. The British Journal of Dermatology 179 (3): 615-22.